Nancy G. Iskander

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

fastp: an ultra-fast all-in-one FASTQ preprocessor

The evidence framework for precision cancer medicine

The Emerging Role of “Liquid Biopsies,” Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations

Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers

Tumour heterogeneity in the clinic

Current and future perspectives of liquid biopsies in genomics-driven oncology

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

The MAPK pathway across different malignancies: A new perspective

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay

Neuropathic Pain: From Mechanisms to Treatment

Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling

Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative